In cancer stem cells (CSCs), STAT3 gain-of-function mutations or persistent activation further amplify these effects by promoting the expression of stemness-related transcription factors such as NANOG, SOX2, and OCT4, which are critical for maintaining the CSC phenotype [43]. This evidence concerns the gene SOX2 and cancer.